| Literature DB >> 35502340 |
Cem Peskersoy1, Aybeniz Oguzhan1, Onder Gurlek2.
Abstract
Objective: This study investigated the effects of flowable resin composites (FCR) on the restoration of noncarious cervical lesions (NCCL) and their impact on periodontal tissues. Materials andEntities:
Mesh:
Substances:
Year: 2022 PMID: 35502340 PMCID: PMC9056215 DOI: 10.1155/2022/6476597
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Materials used in the study.
| Material | Brand | Group | Batch No. | Contents |
|---|---|---|---|---|
| Self-adhering flowable composite group 1, Vertise flow | Kerr Corp, (Orange Co. CA, USA) | VF | 5079369 | GPDM, 4-META, UDMA, BisGMA, photoinitiator, 70% ytterbium fluoride, barium aluminosilicate glass, colloidal silica, and prepolymerized filler |
| Fluoride-releasing flowable composite group 2, Nexcomp flow | Meta BioMED, (Chungbuk, S. Korea) | NF | 1107222 | Bis-GMA, UDMA, Bis-EMA TMPTMA, 60%, 0.8 |
| Microhybrid flowable composite group 3, Nova Compo SF | Imicryl Corp. (Konya, TURKEY) | GF | 15278 | 31% methacrylate (UDMA, Bis-MEPP, TEGDMA), 69% silicon dioxide, 50% strontium glass, pigments, and photoinitiators |
| Universal bonding (adhesive) system, Single Bond Universal | 3M ESPE (St. Paul, MN, USA) | — | 622643 | MDP, phosphate monomer, HEMA, dimethacrylate resin, silane, ethanol, copolymer (polyalcenoic acid), water, and initiators |
| Acid (etch) gel scotch bond gel | 3M ESPE (St. Paul, MN, USA) | — | 3741904 | 37% orthophosphoric acid, benzalconium chloride |
Figure 1Materials used in the study. (a) Vertise flow (self-adhering FCR). (b) Nova Compo SF (microhybrid FCR). (c) Nexcomp flow (fluoride-releasing FCR). (d) Single Bond Universal (all-in-one self-etch adhesive).
USPHS (Ryge) clinical evaluation criteria.
| Category | Score | Clinical evaluation criteria |
|---|---|---|
| Surface roughness and gloss | 1-Alpha | Surface of restoration is neat and smooth |
| 2-Bravo | Slightly uneven and rough surface | |
| 3-Charlie | There are deep notches and irregular grooves on the surface | |
|
| ||
| Marginal coloration | 1-Alpha | There is no color difference between the restoration and the tooth |
| 2-Bravo | There is a slight discoloration | |
| 3-Charlie | The discoloration progresses towards the cavity | |
|
| ||
| Color/shade matching | 1-Alpha | No change in color, shade, or transparency of the restoration |
| 2-Bravo | Slight change of color (up to 2 shades) | |
| 3-Charlie | Significant change of color (more than to 2 shades) | |
|
| ||
| Anatomical form | 1-Alpha | Restoration is sound and continuous |
| 2-Bravo | Slight discontinuity on marginal ridges but clinically acceptable | |
| 3-Charlie | Wear and deformation in restoration are present | |
|
| ||
| Retention of restoration | 1-Alpha | Restoration is sound and present |
| 2-Bravo | Restoration has repairable cracks and/or wear | |
| 3-Charlie | Significant parts or all of the restoration have been lost | |
|
| ||
| Marginal adaptation | 1-Alpha | No visible crevice and the explorer do not catch at interfaces |
| 2-Bravo | There is a small crevice, and the explorer falls into it | |
| 3-Charlie | Explorer is advancing towards dentin or base of restoration | |
|
| ||
| Secondary caries | 1-Alpha | The tooth is sound |
| 2-Bravo | Localized demineralization areas are present | |
| 3-Charlie | Secondary caries are present | |
Figure 2Case design of the study. (a) Clinical condition of the teeth and collecting GCF before treatment. (b) Post-op. GCF sampling immediately after the restoration phase. (c) 1-week follow-up GCF collecting. (d) 1-month follow-up control and sample collecting.
Gingival crevicular fluid (GCF) volumes, interleukin (IL-1, IL-1β, and IL-10), immunoglobulin (IgA, IgM), and cytokine (osteoprotegerin (OPG)) levels before and after treatment obtained from the study levels at 1-week and 1-month follow-ups.
| Biochemical parameter | Flowable composite materials | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertise flow (VF) | Nexcomp flow (NF) | Nova Compo SF (SF) | ||||||||||
| Evaluation periods | Pre-T. | Post-T. | 1 week | 1 month | Pre-T. | Post-T. | 1 week | 1 month | Pre-T. | Post-T. | 1 week | 1 month |
| Gingival crevicular fluid (GCF) volume (pg/ml) | 0.95 (0.02) | 1.20 (0.07) | 1.38 (0.06)a |
| 0.98 (0.03) | 1.30 (0.07) | 1.21 (0.15)a |
| 0.98 (0.07) | 1.18 (0.07) | 1.34 (0.09) |
|
| Interleukin-1 (IL-1) (pg/ml) | 31.58 (5.66) | 129.84 (11.16) | 115.88b (11.59) | 57.49c (7.72) | 32.28 (6.84) | 137.27 (11.01) | 170.21b (11.60) | 82.79c (8.72) | 33.47 (4.68) | 119.68 (9.98) | 92.39b (8.27) | 36.32c (8.32) |
|
| ||||||||||||
| Interleukin-1beta (IL-1 | 7.83 (1.75) | 35.97 (4.65) | 17.72d (4.42) |
| 8.19 (1.20) | 39.44 (6.31) | 31.00d (6.67) |
| 7.41 (2.13) | 36.55 (4.48) | 18.23d (3.22) |
|
| Interleukin-10 (IL-10) (pg/ml) | 4.76 (0.82) | 14.45 (0.84) | 5.79 (0.29) |
| 5.16 (0.81) | 12.85 (0.62) | 6.04 (0.94) |
| 5.15 (0.94) | 14.15 (0.65) | 5.50 (0.10) |
|
| Immunoglobulin A (IgA) (mg/ml) | 2.56 (0.51) | 2.68 (0.30) | 2.72 (0.38) | 2.58 (0.14) | 2.61 (0.42) | 2.70 (0.22) | 2.59 (0.20) | 2.45 (0.20) | 2.48 (0.28) | 2.65 (0.25) | 2.56 (0.33) | 2.44 (0.15) |
| Immunoglobulin M (IgM) (mg/ml) | 0.93 (0.22) | 1.35 (0.29) | 0.94 (0.51) | 0.92 (0.05) | 0.92 (0.18) | 1.23 (0.20) | 0.94 (0.26) | 1.00 (0.20) | 0.98 (0.21) | 1.13 (0.29) | 1.02 (0.28) | 0.96 (0.22) |
|
| ||||||||||||
| Osteoprotegerin (OPG) (pg/ml) | 71.68 (6.22) | 108.18 (10.92) | 140.55f (9.65) | 179.99 g (18.86) | 75.48 (8.19) | 112.41 (7.94) | 134.90f (13.14) | 166.50g (15.96) | 69.14 (5.81) | 109.51 (11.84) | 153.55f (19.42) | 184.66g (11.48) |
Standard deviations are given in parentheses. Different superscript letters indicate statistical differences between groups (p < 0.05). Values written in italics indicate positive correlations before and after treatment.
USPHS scores of restorations made with different flowable composites applied in the study after treatment (Post-op.), 1-week, 1-month, and 12-month follow-ups.
| USPHS criteria | Flowable composite materials | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertise flow (VF) | Nexcomp flow (NF) | Nova Compo SF (SF) | ||||||||||
| Evaluation periods | Post-op. | 1st week | 1st month | 12th month | Post-op. | 1st week | 1st month | 12th month | Post-op. | 1st week | 1st month | 12th month |
| Surface roughness and gloss |
|
|
|
|
|
|
| 2 a,b |
|
|
|
|
|
| ||||||||||||
| Marginal coloring |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Color/shade matching |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Anatomical form |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Retention of restoration |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Marginal adaptation |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Secondary |
|
|
|
|
|
|
|
|
|
|
|
|
Italicized numbers present the average USPHS score of the selected criteria. Case numbers and scores are given in parentheses. (A: Alpha, B: Bravo, and C: Charlie). The same superscript letters indicate statistical differences between groups (p < 0.05).